Gilead Sciences easily beat third-quarter forecasts late Wednesday, and raised its outlook in a move that could bolster ...

Gilead Sciences Inc (NASDAQ:GILD) recently filed its 10-Q report ... This growth is largely due to higher demand and average ...

Citi initiated coverage of Gilead (GILD) with a Buy rating and $125 price target The firm says that despite the stock’s near-term ...

Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio. Read why I ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...

Gilead Sciences Inc (NASDAQ:GILD) stock is trading higher on Thursday after the company reported better-than-expected ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

Nov 6 (Reuters) - Gilead Sciences (GILD.O), opens new tab reported third-quarter ... Third-quarter sales of HIV drug Biktarvy ...

(Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead’s third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% ...

--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq ... including 13% year-over-year growth for Biktarvy. Based on this very strong topline growth and disciplined operating expense management ...